Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNurix Therapeutics, Inc.
About this trial
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Eligibility criteria
Qualifiers
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Adequate organ and bone marrow function
Measurable disease by computed tomography (CT) per iwCLL
For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
Disqualifiers
Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
Trial design
Treatments tested in this trial
- NX-5948
- venetoclax
- rituximab
- obinutuzumab
Treatment groups
150 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov